Literature DB >> 22958088

AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery.

Suzanne M Connolly, Diane R Baker, Brett M Coldiron, Michael J Fazio, Paul A Storrs, Allison T Vidimos, Mark J Zalla, Jerry D Brewer, Wendy S Begolka, Timothy G Berger, Michael Bigby, Jean L Bolognia, David G Brodland, Scott Collins, Terrence A Cronin, Mark V Dahl, Jane M Grant-Kels, C W Hanke, George J Hruza, William D James, Clifford W Lober, Elizabeth I McBurney, Scott A Norton, Randall K Roenigk, Ronald G Wheeland, Oliver J Wisco.   

Abstract

The appropriate use criteria process synthesizes evidence-based medicine, clinical practice experience, and expert judgment. The American Academy of Dermatology in collaboration with the American College of Mohs Surgery, the American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery has developed appropriate use criteria for 270 scenarios for which Mohs micrographic surgery (MMS) is frequently considered based on tumor and patient characteristics. This document reflects the rating of appropriateness of MMS for each of these clinical scenarios by a ratings panel in a process based on the appropriateness method developed by the RAND Corp (Santa Monica, CA)/University of California-Los Angeles (RAND/UCLA). At the conclusion of the rating process, consensus was reached for all 270 (100%) scenarios by the Ratings Panel, with 200 (74.07%) deemed as appropriate, 24 (8.89%) as uncertain, and 46 (17.04%) as inappropriate. For the 69 basal cell carcinoma scenarios, 53 were deemed appropriate, 6 uncertain, and 10 inappropriate. For the 143 squamous cell carcinoma scenarios, 102 were deemed appropriate, 7 uncertain, and 34 inappropriate. For the 12 lentigo maligna and melanoma in situ scenarios, 10 were deemed appropriate, 2 uncertain, and 0 inappropriate. For the 46 rare cutaneous malignancies scenarios, 35 were deemed appropriate, 9 uncertain, and 2 inappropriate. These appropriate use criteria have the potential to impact health care delivery, reimbursement policy, and physician decision making on patient selection for MMS, and aim to optimize the use of MMS for scenarios in which the expected clinical benefit is anticipated to be the greatest. In addition, recognition of those scenarios rated as uncertain facilitates an understanding of areas that would benefit from further research. Each clinical scenario identified in this document is crafted for the average patient and not the exception. Thus, the ultimate decision regarding the appropriateness of MMS should be determined by the expertise and clinical experience of the physician.
© 2012 by the American Society for Dermatologic Surgery, Inc., and the American Academy of Dermatology, Inc. Published by Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22958088     DOI: 10.1111/j.1524-4725.2012.02574.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  9 in total

1.  Squamous cell carcinoma with aggressive subclinical extension: 5-year retrospective review of diagnostic predictors.

Authors:  Alina Goldenberg; Arisa Ortiz; Silvia S Kim; S Brian Jiang
Journal:  J Am Acad Dermatol       Date:  2015-04-01       Impact factor: 11.527

2.  Patient Factors and Their Association with Nonmelanoma Skin Cancer Morbidity and the Performance of Self-skin Exams: A Cross-Sectional Study.

Authors:  Kyle T Amber; Romi Bloom; Mohammad-Ali Yazdani Abyaneh; Leyre A Falto-Aizpurua; Martha Viera; Martin N Zaiac; Keyvan Nouri; Shasa Hu
Journal:  J Clin Aesthet Dermatol       Date:  2016-09-01

Review 3.  The Role of Classical and Novel Forms of Vitamin D in the Pathogenesis and Progression of Nonmelanoma Skin Cancers.

Authors:  Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Zorica Janjetovic; Tae-Kang Kim; Radomir M Slominski; Robert C Tuckey; Rebecca S Mason; Anton M Jetten; Purushotham Guroji; Jörg Reichrath; Craig Elmets; Mohammad Athar
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

4.  Computed tomography-based flap brachytherapy for non-melanoma skin cancers of the face.

Authors:  Emile Gogineni; Haocheng Cai; Dawn Carillo; Zaker Rana; Beatrice Bloom; Louis Potters; Hani Gaballa; Maged Ghaly
Journal:  J Contemp Brachytherapy       Date:  2021-02-18

Review 5.  Management of Skin Cancer in the High-Risk Patient.

Authors:  James W Behan; Adam Sutton; Ashley Wysong
Journal:  Curr Treat Options Oncol       Date:  2016-12

Review 6.  Surgical treatment of basal cell carcinoma: an algorithm based on the literature.

Authors:  Flávio Barbosa Luz; Camila Ferron; Gilberto Perez Cardoso
Journal:  An Bras Dermatol       Date:  2015-06-01       Impact factor: 1.896

7.  Analysis of effectiveness of a surgical treatment algorithm for basal cell carcinoma.

Authors:  Flávio Barbosa Luz; Camila Ferron; Gilberto Perez Cardoso
Journal:  An Bras Dermatol       Date:  2016 Nov-Dec       Impact factor: 1.896

Review 8.  Emerging concepts and recent advances in basal cell carcinoma.

Authors:  Mariam Totonchy; David Leffell
Journal:  F1000Res       Date:  2017-12-04

9.  Nasal Reconstruction of Post-Mohs Defects >1.5 cm in a Single Cosmetic Subunit Under Local Anesthesia by a Combination of Plastic Surgeon and Mohs Surgeon Team: A Cross-sectional Study and Review of Algorithmic Nasal Defect Closures.

Authors:  Omeed M Memar; Benjamin Caughlin
Journal:  Plast Reconstr Surg Glob Open       Date:  2019-06-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.